-
CSR Summary
N/A
-
NCT02257736
-
Primary Citation
-
You are not logged in.
Please login to continue selecting trials.
Trial Information
Generic NameApalutamideProduct NameERLEADA®Therapeutic AreaCancers and Other NeoplasmsEnrollment982% FemaleN/A% White75.2%
Product ClassNonsteroidal antiandrogenSponsor Protocol Number56021927PCR3001Data PartnerJohnson & JohnsonCondition StudiedNeoplasms, ProstaticMean/Median Age (Years)71.1
Supporting Documentation
- Collected Datasets Available
- Data Definition Specification Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available
Approved Data Requests Associated with this Trial
- 2024-0372 : Development of a clinical decision-support algorithm based on Network Meta-Analysis and Decision Curve Analysis for patients with metastatic castration-resistant prostate cancer (mCRPC)
- 2023-5274 : Statin use and outcomes in patients treated in the SPARTAN, TITAN and ACIS trial
- 2023-5236 : Understanding the Symptom Experience of Abiraterone and the Effect on Quality of Life for Men with metastatic Prostate Cancer.
- 2023-5198 : Evaluation of G-computation and conformal prediction to provide early signs of efficacy in single arm trial with time to event outcomes
- 2023-5195 : Predictive modeling of adverse events and symptoms patterns in large scale clinical trials
- 2023-5187 : The association between antibiotics exposure and outcomes in men with prostate cancer
- 2023-5173 : Improving Outcome in Advanced Prostate Cancer: a Pooled Analysis of Randomized Controlled Trials
- 2023-5129 : Effect of Prior Local Therapy on Response to First Line Systemic Therapy in Men with Metastatic Castrate Resistant Prostate Cancer
- 2022-5125 : Risk of therapy-related adverse events in men on abiraterone or enzalutamide, a meta-analysis of clinical trial data
- 2022-5106 : Assessing the Androgen indifferent prostate cancer patients response to novel antiandrogen-based regimen or taxanes
- 2022-5058 : The impact of long-term proton pump inhibitors use on the prognosis of patients receiving Androgen-annihilation therapy.
- 2022-5008 : Analytical Approaches of Time to Event of Patient-reported Outcomes: A Case Study in Patients with Metastatic Castration-resistant Prostate Cancer
- 2022-4974 : Association between adverse events and change in quality-of-life scores in phase II-III cancer clinical trials
- 2022-4868 : Comparison of Outcomes in Patients treated with prior radical prostatectomy versus prior radiation therapy: a pooled analysis of ACIS and COU-AA302